No products in the cart.
Pre-made Afutuzumab benchmark antibody ( Whole mAb, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-013
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Afutuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Obinutuzumab (called afutuzumab until 2009) is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment.
| Products Name (INN Index) | Pre-Made Afutuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody |
|---|---|
| INN Name | Afutuzumab |
| Target | MS4A1 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 3pp3:HL:IK/3pp4:HL |
| 99% SI Structure | 6y9a:HL |
| 95-98% SI Structure | 6y97:HL |
| Year Proposed | 2008 |
| Year Recommended | 2011 |
| Companies | GLYCART Biotechnology,Biogen Idec,Chugai Pharmaceutical,Dana-Farber Cancer Institute,Genentech,Lymphoma Academic Research Organisation,Nippon Shinyaku,OHSU Knight Cancer Institute,Pharmacyclics,Polis |
| Conditions Approved | Chronic lymphocytic leukaemia,Follicular lymphoma,Non-Hodgkin's lymphoma |
| Conditions Active | Diffuse large B cell lymphoma,CNS cancer,Graft-versus-host disease,Lupus nephritis,Mantle-cell lymphoma,Waldenstrom's macroglobulinaemia |
| Conditions Discontinued | Primary biliary cirrhosis |
| Development Tech | GlycoMAb Technology |
| Previous Name | Obinutuzumab |
| Gm Offical Target Name | MS4A1/CD20 |
| Package |
Previous slide
Next slide
